Topical/inhaled corticosteroid
Fluticasone
Brand names: Flixotide, Flixonase, Flutiform, Cutivate
Adult dose
Dose: Asthma inhaled: 100–500 micrograms BD (propionate) or 92–184 micrograms OD-BD (furoate). Nasal: 1–2 sprays OD. Topical (Cutivate): apply OD–BD
Route: Inhaled/Nasal/Topical
Frequency: OD-BD
Clinical pearls
- Asthma, COPD (with LABA), allergic rhinitis, eczema/psoriasis
- Rinse mouth after inhaled use
Contraindications
- Untreated chest infection
- Local sensitivity
Side effects
- Oral candidiasis (inhaled)
- Hoarseness
- Adrenal suppression at high dose
- Skin atrophy (topical)
- Epistaxis (nasal)
Interactions
- Strong CYP3A4 inhibitors (ritonavir, ketoconazole) — Cushing's reported
Monitoring
- Symptom control
- Growth in children
Reference: BNF; BTS/SIGN; NICE NG80/NG115; https://bnf.nice.org.uk/drugs/fluticasone/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Pathways
- Acute Asthma in Adults · BTS/SIGN British Guideline on Asthma 2019; NICE NG80
- Pulmonary Embolism Assessment · NICE NG158; ESC 2019 PE Guidelines
- Acute Exacerbation of COPD (AECOPD) · NICE NG115; GOLD 2024
- Spontaneous Pneumothorax (Adult) · BTS Pleural Disease 2023
- Atypical Pneumonia (Legionella / Mycoplasma / Chlamydophila) · BTS 2023; IDSA
- COPD Exacerbation Management · NICE NG115 / GOLD 2024